Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer

Phase II Trial of Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00193388

Enrollment

100

Registered

2005-09-19

Start date

2002-09-30

Completion date

2007-02-28

Last updated

2010-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Brief summary

In this phase II trial, we will evaluate the weekly schedule of topotecan in the second-line treatment of patients with small cell lung cancer

Detailed description

Upon determination of eligibility, all patients will be receive: * Topotecan

Interventions

DRUGTopotecan

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

To be included in this study, you must meet the following criteria: * Small Cell Lung cancer * Progression after one previous regimen * Measurable or evaluable disease * Able to perform activities of daily living with assistance * Adequate bone marrow, liver and kidney function * No more than three previous courses of radiation therapy * Accessible for treatment and follow up * Must give written informed consent prior to study entry

Exclusion criteria

You cannot participate in this study if any of the following apply to you: * Central nervous system involvement * Serious or active infection * Serious underlying medical condition * Other active neoplasms Please note: There are additional inclusion/

Design outcomes

Primary

Measure	Time frame
Overall response rate	—

Secondary

Measure	Time frame
Median survival	—
1-year survival	—
Symptomatic improvement	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026